🇺🇸 FDA
Patent

US 9637524

Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector

granted A61KA61K2039/5258A61K2039/53

Quick answer

US patent 9637524 (Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector) held by The Regents of the University of California expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/5258, A61K2039/53, A61K2039/541, A61K2039/542